Rheopheresis: A new therapeutic approach in severe calciphylaxis

Uremic calciphylaxis, also called calcific uraemic arteriolopathy (CUA), is a rare disease with a poor prognosis (mortality between 45% and 80%). Treatment is currently not standardized, and is based mainly on risk factor control, often with administration of sodium thiosulfate. We report the use of rheopheresis, a double filtration apheresis technique, specifically designed to improve blood rheology and tissue perfusion, as adjunctive therapy in eight patients with severe CUA.

[1]  S. Nigwekar,et al.  The Successful Use of Apixaban in Dialysis Patients with Calciphylaxis Who Require Anticoagulation: A Retrospective Analysis , 2018, American Journal of Nephrology.

[2]  F. Provôt,et al.  Rheopheresis for Adjuvant Treatment in Resistant Calciphylaxis , 2018, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[3]  C. Harris,et al.  Multi-intervention management of calcific uremic arteriolopathy in 24 patients , 2018, Clinical kidney journal.

[4]  D. Christiadi,et al.  Calciphylaxis in a dialysis patient successfully treated with high-dose vitamin K supplementation , 2017, Clinical kidney journal.

[5]  M. Daudon,et al.  Efficacy of intralesional sodium thiosulfate injections for disabling tumoral calcinosis: Two cases. , 2017, Seminars in arthritis and rheumatism.

[6]  S. Booth,et al.  Vitamin K-Dependent Carboxylation of Matrix Gla Protein Influences the Risk of Calciphylaxis. , 2017, Journal of the American Society of Nephrology : JASN.

[7]  N. Dunbar,et al.  临床实践中治疗性单采术应用指南——基于美国血浆置换学会编写委员会的循证策略：第七版 , 2016 .

[8]  N. Dunbar,et al.  Guidelines on the Use of Therapeutic Apheresis in Clinical Practice–Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue , 2016, Journal of clinical apheresis.

[9]  M. Kamdar,et al.  Calciphylaxis: risk factors, diagnosis, and treatment. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  P. Parfrey,et al.  The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[11]  C. Herzog,et al.  Quantifying a Rare Disease in Administrative Data: The Example of Calciphylaxis , 2014, Journal of General Internal Medicine.

[12]  David Steele,et al.  Intralesional sodium thiosulfate for the treatment of calciphylaxis. , 2013, JAMA dermatology.

[13]  S. Brunelli,et al.  Sodium thiosulfate therapy for calcific uremic arteriolopathy. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[14]  M. Rudnicki,et al.  Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  S. Soroka,et al.  Oral Sodium Thiosulfate as Maintenance Therapy for Calcific Uremic Arteriolopathy: A Case Series , 2013, American Journal of Nephrology.

[16]  A. Ramunni,et al.  Acute and chronic effects of therapeutic apheresis. , 2013, Atherosclerosis. Supplements.

[17]  A. Levin,et al.  Multi-intervention management of calciphylaxis: a report of 7 cases. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  H. Derendorf,et al.  Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[19]  M. Ketteler,et al.  Calciphylaxis: a still unmet challenge. , 2011, Journal of nephrology.

[20]  J. Floege,et al.  Sodium thiosulfate in the treatment of calcific uremic arteriolopathy , 2009, Nature Reviews Nephrology.

[21]  H. Schmid-schönbein,et al.  Effects of Fibrinogen and α2‐Macroglobulin and Their Apheretic Elimination on General Blood Rheology and Rheological Characteristics of Red Blood Cell Aggregates , 2008, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[22]  C. Raymond,et al.  Sodium thiosulfate, bisphosphonates, and cinacalcet for treatment of calciphylaxis. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[23]  M. Pittelkow,et al.  Calciphylaxis: natural history, risk factor analysis, and outcome. , 2007, Journal of the American Academy of Dermatology.

[24]  C. Diehm,et al.  Rheopheresis in Patients with Critical Limb Ischemia––Results of an Open Label Prospective Pilot Trial , 2005, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[25]  J. Dear,et al.  Calciphylaxis , 2003, The Lancet.

[26]  P. Walter,et al.  The Effect of Membrane Differential Filtration on the Colloid Osmotic Pressure in Patients with Age‐Related Macular Degeneration: Significance to Visual Function? , 2003, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[27]  A. Fine,et al.  Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. , 2002, Kidney international.

[28]  P. Hill,et al.  Calcific uraemic arteriolopathy: local treatment and hyperbaric oxygen therapy. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  K. Burns,et al.  Hyperbaric oxygen in the treatment of calciphylaxis: a case series. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[30]  C. Stehman-Breen,et al.  Risk factors and mortality associated with calciphylaxis in end-stage renal disease. , 2001, Kidney international.

[31]  J. Berrouschot,et al.  Rheopheresis: rheologic, functional, and structural aspects. , 2000, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[32]  G. Siami,et al.  Intensive tandem cryofiltration apheresis and hemodialysis to treat a patient with severe calciphylaxis, cryoglobulinemia, and end-stage renal disease. , 1999, ASAIO journal.

[33]  F. Llach.  Calcific uremic arteriolopathy (calciphylaxis): an evolving entity? , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[34]  S. Myers,et al.  Calciphylaxis in patients on hemodialysis: a prevalence study. , 1997, Surgery.